ArticleJournal of virology2000
Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs.
Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 88 citations in OpenAlex.
- Swine Group A rotavirus vaccines: current status, adjuvant strategies, challenges, and future perspectives.Frontiers in veterinary science · 2026Review
- Design of multi-epitope vaccine against porcine rotavirus using computational biology and molecular dynamics simulation approaches.Virology journal · 2024Article
- Correlates of immune protection against human rotaviruses: natural infection and vaccination.Archives of virology · 2024Review
- Parenteral, non-live rotavirus vaccine: recent history and future perspective.Clinical and experimental vaccine research · 2021Review
- Rotavirus vaccines: why continued investment in research is necessary.Current clinical microbiology reports · 2018Article
- Development of a human rotavirus induced diarrhea model in Chinese mini-pigs.World journal of gastroenterology · 2016Article
- Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana.Virology journal · 2015Article
- Evidence for a common mucosal immune system in the pig.Molecular immunology · 2015Review
- Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings.Mucosal immunology · 2015Review
- Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.Human vaccines & immunotherapeutics · 2014Article
- Chimaeric virus-like particles derived from consensus genome sequences of human rotavirus strains co-circulating in Africa.PloS one · 2014Article
- Review
- Virus-like particles: the new frontier of vaccines for animal viral infections.Veterinary immunology and immunopathology · 2012Review
- Development of a Bacillus subtilis-based rotavirus vaccine.Clinical and vaccine immunology : CVI · 2010Article
- An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model.Clinical and vaccine immunology : CVI · 2010Article
- Qualitative and quantitative characteristics of rotavirus-specific CD8 T cells vary depending on the route of infection.Journal of virology · 2008Article
- Article
- Why does the world need another rotavirus vaccine?Therapeutics and clinical risk management · 2008Article
- Rotavirus vaccines: recent developments and future considerations.Nature reviews. Microbiology · 2007Review
- Preparation of recombinant vaccines.Biotechnology annual review · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
We investigated the immunogenicity of recombinant double-layered rotavirus-like particle (2/6-VLPs) vaccines derived from simian SA11 or human (VP6) Wa and bovine RF (VP2) rotavirus strains. The 2/6-VLPs were administered to gnotobiotic pigs intranasally (i.n.) with a mutant Escherichia coli heat-labile toxin, LT-R192G (mLT), as mucosal adjuvant. Pigs were challenged with virulent Wa (P1A[8],G1) human rotavirus at postinoculation day (PID) 21 (two-dose VLP regimen) or 28 (three-dose VLP regimen). In vivo antigen-activated antibody-secreting cells (ASC) (effector B cells) and in vitro antigen-reactivated ASC (derived from memory B cells) from intestinal and systemic lymphoid tissues (duodenum, ileum, mesenteric lymph nodes [MLN], spleen, peripheral blood lymphocytes [PBL], and bone marrow lymphocytes) collected at selected times were quantitated by enzyme-linked immunospot assays. Rotavirus-specific immunoglobulin M (IgM), IgA, and IgG ASC and memory B-cell responses were detected by PID 21 or 28 in intestinal and systemic lymphoid tissues after i.n. inoculation with two or three doses of 2/6-VLPs with or without mLT. Greater mean numbers of virus-specific ASC and memory B cells in all tissues prechallenge were induced in pigs inoculated with two doses of SA11 2/6-VLPs plus mLT compared to SA11 2/6-VLPs without mLT. After challenge, anamnestic IgA and IgG ASC and memory B-cell responses were detected in intestinal lymphoid tissues of all VLP-inoculated groups, but serum virus-neutralizing antibody titers were not significantly enhanced compared to the challenged controls. Pigs inoculated with Wa-RF 2/6-VLPs (with or without mLT) developed higher anamnestic IgA and IgG ASC responses in ileum after challenge compared to pigs inoculated with SA11 2/6-VLPs (with or without mLT). Three doses of SA 11 2/6-VLP plus mLT induced the highest mean numbers of IgG memory B cells in MLN, spleen, and PBL among all groups postchallenge. However, no significant protection against diarrhea or virus shedding was evident in any of the 2/6-VLP (with or without mLT)-inoculated pigs after challenge with virulent Wa human rotavirus. These results indicate that 2/6-VLP vaccines are immunogenic in gnotobiotic pigs when inoculated i.n. and that the adjuvant mLT enhanced their immunogenicity. However, i.n. inoculation of gnotobiotic pigs with 2/6-VLPs did not confer protection against human rotavirus challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.